1. Pink Sheet
  2. >>Vaccines

EU HTA Regulation: Don’t Forget About Vaccines, Industry Warns

 
• By Eliza Slawther

Europe’s vaccines industry wants to make sure immunizations “are not forgotten” by policymakers who are overseeing the EU Health Technology Assessment Regulation. It has highlighted several nuances of vaccines that should be addressed over the coming years.

The vaccines industry warns that the EU HTA Regulation could pose challenges for immunizations (Shutterstock)
Key Takeaways
  • The vaccines industry wants EU policymakers to ensure that the EU Health Technology Assessment Regulation is suitable for immunizations.
  • An executive from CSL Seqirus said that national immunization expert groups should be included in joint clinical assessments under the HTA Regulation.
  • Industry group Vaccines Europe has also set out recommendations for policymakers in relation to vaccines within the context of the EU HTA framework.

Vaccines will fall within the scope of the new EU Health Technology Assessment (HTA) Regulation from 2030, but industry wants changes to be made to the methods used to perform the joint clinical assessments

“We want to have this conversation today, because we hope that by having these discussions, we will raise awareness and ensure those things are not forgotten,” Anna Viceré, associate director, public affairs & access policy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

Califf In Conversation: ‘Decimated’ US FDA Teams Endanger Innovation

 
• By Barnaby Pickering

Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development.

US FDA Vaccine Framework Coming In Weeks, But Details Vague

 
• By Sarah Karlin-Smith

New CBER Director Prasad will "unleash a massive" framework on vaccines, FDA Commissioner Marty Makary said 15 May, raising questions about the impact on products nearing approval.

FDA Use Of Artificial Intelligence Will Help US Retain Biotech Leadership

 
• By Sue Sutter and Derrick Gingery

At a House subcommittee hearing, HHS Secretary Robert F. Kennedy Jr. rebutted lawmaker concerns that NIH cuts will drive research and scientists to other countries and said he does not want to advise parents on vaccinating children for measles, chickenpox or polio.

Safety Review Prompts EMA to Suspend Ixchiq Chikungunya Vaccine For Seniors

 
• By Neena Brizmohun

The European Medicines Agency is investigating whether Valneva’s Ixchiq is safe to use in the elderly, following reports of 17 serious adverse events, including two cases resulting in death, in people aged 62 to 89 years who received the vaccine. This follows actions by US and French authorities last month regarding Ixchiq’s use in people over 65.

More from R&D